Business Context and Reporting Period
This Form 8-K filing by Bristol-Myers Squibb Company was submitted on June 20, 2016. The report discloses a significant executive appointment and associated compensatory arrangements effective June 21, 2016.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on personnel changes and executive compensation details.
Material Changes
The primary material change reported is the promotion of Murdo Gordon from Senior Vice President and Head of Worldwide Markets to the newly created position of Executive Vice President and Chief Commercial Officer. Mr. Gordon, who joined the company in 1989, previously served as President of U.S. operations (2013–2015) and Senior Vice President of Oncology and Immunoscience (2011–2013).
Management Commentary and Compensation Details
Effective June 21, 2016, Mr. Gordon's compensation package includes:
- Base Salary: $786,500 annually.
- Target Incentive Award: 100% of base salary under the Senior Executive Performance Incentive Plan, contingent on pre-established performance goals.
- Long-Term Incentives: Eligibility for performance share units and market share units under the 2012 Stock Award and Incentive Plan.
- Severance: Change-in-control and severance benefits consistent with those provided to Named Executive Officers in the event of involuntary termination without cause.
The filing states there are no related party transactions or other arrangements influencing this selection.
Investor Verification Checklist
- Verify the effective date of the new role (June 21, 2016) against internal corporate calendars.
- Review the attached press release (Exhibit 99.1) for additional strategic context regarding the new Chief Commercial Officer role.
- Confirm the specific performance goals tied to the 100% target incentive award in future proxy statements or earnings calls.
- Note that this filing contains no financial results; refer to the most recent 10-Q or 10-K for fiscal metrics.